Johnson & Johnson announced Phase 2b DUET-UC and DUET-CD results on May 5, 2026, showing JNJ-4804 (co-antibody targeting IL-23 and TNF-α) achieved higher clinical remission (50.8% in CD overall) and endoscopic response rates vs. golimumab and guselkumab in refractory IBD patients.
In highly refractory CD patients (failed ≥2 therapies), JNJ-4804 nearly doubled clinical remission and >60% higher endoscopic response vs. comparators.
Despite some sources noting mixed efficacy or trial misses in overall populations, J&J is initiating Phase 3 DUET ENCORE-CD and ENCORE-UC trials focusing on refractory patients.
JNJ-4804 is the first fixed-dose co-antibody combining golimumab and guselkumab mechanisms for synergistic IBD treatment.
Data presented at Digestive Disease Week (DDW) 2026 supports addressing unmet needs in treatment-experienced UC and CD patients.